In terms of human pancreatic cancer, ABT-737 and obatoclax, which inhibits Bcl-2, Bcl-xL, and Mcl-1, were shown to enhance the TRAIL sensitivity of pancreatic cancer cell lines [43, 44]. Here, BCL2 is linked to familial pancreatic carcinoma.